Valeant Bondholders Eyeing Value After Plunge on Drug Accounting

Updated on
  • Bond investors say rising cashflow supports debt prices
  • Some holders see buying opportunity after yields surged

Bond investors are starting to see value in embattled Valeant Pharmaceuticals International Inc. after heightened scrutiny of its business and accounting practices sent its stock and debt prices tumbling.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.